Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
批准号:
8664206
负责人:
RICHARD J BUCALA
金额:
$41.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-01 至 2019-03-31
关键词:
AccountingAntigensAntimalarialsApoptosisBindingBinding ProteinsBiological ModelsBloodBrugiaCD4 Positive T LymphocytesCD44 geneCellsCessation of lifeCommunicable DiseasesCytokine SignalingDataDevelopmentEnvironmentErythrocytesEvaluationFoundationsGenerationsGenesGenomicsGoalsHelper-Inducer T-LymphocyteHookwormsHumanImmune responseImmunityImmunizationInfectionInflammatoryInflammatory ResponseInvestigationKnowledgeLeadLeishmaniaMalariaMalaria VaccinesMediatingMemoryMigration Inhibitory FactorMolecularMusN-terminalOrthologous GeneParasitemiaParasitesPathway interactionsPlasmodiumProductionPropertyProteinsRNAReceptor ActivationResearchRoleSignal PathwaySignal TransductionSporozoitesStagingT cell responseT memory cellT-Cell DevelopmentT-LymphocyteTherapeuticToll-like receptorsTransducersVaccine TherapyVaccinesWorkadaptive immunitybasecytokinedesignexhaustionexperiencefilariaimmunoregulationinhibitor/antagonistinsightmemory CD4 T lymphocytemouse modelnovelnovel therapeutic interventionpathogenphenylpyruvate tautomerasepublic health relevancereceptorresponsesmall moleculetransmission processvaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY / ABSTRACT
The inability to acquire fully protective immunity against Plasmodium is a chief obstacle to malaria
control. High levels of inflammatory cytokines can inhibit memory T cell development in model systems.
Notably, all Plasmodia species have been found to encode an ortholog of the upstream inflammatory
cytokine, macrophage migration inhibitory factor (MIF). Plasmodium MIF (PMIF) upregulates inflammatory
responses during infection, leading to enhanced activation-induced T cell apoptosis and fewer antigen-
experienced CD4 T cells that become memory cells. This finding suggests that Plasmodia actively interfere
with the generation of malaria-specific memory CD4 T cells to enable parasite persistence and
transmission.
To better understand ineffective immunity to malaria and to provide a foundation for better vaccines,
we will determine the specific role of PMIF in the anti-malarial immune response in three Specific Aims, as
follow: Aim 1. Define the Molecular Basis for the Pro-inflammatory Activation of the Immune
Response by Plasmodium-encoded MIF (PMIF). We hypothesize that PMIF increases inflammatory
responses by activating the host MIF receptor. We will define shared and unique signaling properties of
PMIF versus host MIF and examine the role of the conserved N-terminal region, which mediates binding to
the MIF receptor. We will investigate the action of PMIF on Toll-like and NOD-like receptor activation
pathways, and we will validate our observations in mice infected with a P. berghei ANKA strain lacking its
mif gene. Aim 2. Define the Cellular and Molecular Basis for the Suppression of the Anti-malarial
Adaptive Immune Response by PMIF. We hypothesize that a strong pro-inflammatory environment
during malaria infection favors the generation of terminal effector CD4 T cells at the expense of protective,
memory precursor CD4 T cells. We will elucidate the cytokine and signaling pathways responsible for this
response, examine the role of T follicular helper cells (TFH) and their ability to provide help to B and to T
cells, and analyze T cell exhaustion. Aim 3. Evaluate the Therapeutic Potential of PMIF Neutralization
in Malaria. We will explore the impact of neutralization of PMIF in mouse models of blood-stage and
sporozoite infection. Our approach will include immunization with PMIF by a novel self-amplifying RNA
vaccine and a pharmacologic strategy based on our discovery of a selective, small molecule inhibitor of
PMIF.
These studies will provide insight into how Plasmodia direct the host inflammatory response to
interfere with protective immunity and suggest new strategies for therapeutic immunomodulation and
vaccine development. Conclusions from this work may be generalized to other parasite pathogens, such as
Leishmania, Ancyclostoma, and Brugia, which produce their own closely homologous MIF proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the Pathogenic Contribution of High Genotypic MIF Expression
-
批准号:10402761
-
项目类别:
-
资助金额:$36.48万
-
财政年份:2021
-
负责人:RICHARD J BUCALA
-
依托单位:
Defining the Pathogenic Contribution of High Genotypic MIF Expression
-
批准号:10624334
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2021
-
负责人:RICHARD J BUCALA
-
依托单位:
Defining the Pathogenic Contribution of High Genotypic MIF Expression
-
批准号:10094724
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2021
-
负责人:RICHARD J BUCALA
-
依托单位:
Aging and Innate Immune Mechanisms in Pulmonary Infection
-
批准号:9300969
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2015
-
负责人:RICHARD J BUCALA
-
依托单位:
Aging and Innate Immune Mechanisms in Pulmonary Infection
-
批准号:8967869
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2015
-
负责人:RICHARD J BUCALA
-
依托单位:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
-
批准号:10386832
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2014
-
负责人:RICHARD J BUCALA
-
依托单位:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
-
批准号:8822823
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2014
-
负责人:RICHARD J BUCALA
-
依托单位:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
-
批准号:9815245
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2014
-
负责人:RICHARD J BUCALA
-
依托单位:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
-
批准号:10614419
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2014
-
负责人:RICHARD J BUCALA
-
依托单位:
Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF
-
批准号:9036321
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2014
-
负责人:RICHARD J BUCALA
-
依托单位:
Pilot Projects
-
批准号:8307058
-
项目类别:
-
资助金额:$10.09万
-
财政年份:2011
-
负责人:RICHARD J BUCALA
-
依托单位:
Innate and Adaptive Immune Mechanisms in Arthritis
-
批准号:7616368
-
项目类别:
-
资助金额:$37.24万
-
财政年份:2004
-
负责人:RICHARD J BUCALA
-
依托单位:
INNATE AND ADAPTIVE MECHANISMS IN ARTHRITIS
-
批准号:7185037
-
项目类别:
-
资助金额:$35.27万
-
财政年份:2004
-
负责人:RICHARD J BUCALA
-
依托单位:
Innate and Adaptive Immune Mechanisms in Arthritis
-
批准号:8131660
-
项目类别:
-
资助金额:$47.19万
-
财政年份:2004
-
负责人:RICHARD J BUCALA
-
依托单位:
Suppression of Erythropoiesis in Malaria Infection
-
批准号:7228444
-
项目类别:
-
资助金额:$28.86万
-
财政年份:2004
-
负责人:RICHARD J BUCALA
-
依托单位:
INNATE AND ADAPTIVE MECHANISMS IN ARTHRITIS
-
批准号:6704788
-
项目类别:
-
资助金额:$37.2万
-
财政年份:2004
-
负责人:RICHARD J BUCALA
-
依托单位:
Innate and Adaptive Immune Mechanisms in Arthritis
-
批准号:8522258
-
项目类别:
-
资助金额:$44.83万
-
财政年份:2004
-
负责人:RICHARD J BUCALA
-
依托单位:
Innate and Adaptive Immune Mechanisms in Arthritis
-
批准号:7938682
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2004
-
负责人:RICHARD J BUCALA
-
依托单位:
Innate and Adaptive Immune Mechanisms in Arthritis
-
批准号:8310257
-
项目类别:
-
资助金额:$47.19万
-
财政年份:2004
-
负责人:RICHARD J BUCALA
-
依托单位:
INNATE AND ADAPTIVE MECHANISMS IN ARTHRITIS
-
批准号:7354744
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2004
-
负责人:RICHARD J BUCALA
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: